Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...

Cantor Fitzgerald analyst Olivia Brayer maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target of $480.00. The company’s shares closed ...

Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed ... Rising interest rates, challenges in the U.S. healthcare system, and the inherent risks of drug development have ...

challenges in the U.S. healthcare system, and the inherent risks of drug development have contributed to the sector's underperformance relative to the broader markets during this period. Vertex ...

Vertex Pharmaceuticals (VRTX ... a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system, ranging from #1 (Strong ...

Rising interest rates, challenges in the U.S. healthcare system, and the inherent risks ... it's worth examining whether Vertex stock remains a compelling buy right now. Image source: Getty ...

Ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) were provided by 23 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a concise ...

Vertex Pharmaceuticals Inc. (NASDAQ ... provides easy-to-follow model portfolios designed for wealth accumulation. Curious if VRTX is one of these AI-selected gems? Check out our ProPicks platform ...

Keith Speights has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Why This Beaten-Down Growth ...